BridgeMD
New treatment option for Neuralgia
Official title Treatment of Upper Limb Chronic Neuropathic Pain by Electrical Stimulation of the Brachial Plexus Nerve Roots
ClinicalTrials.gov ID: NCT05817786
What this study is testing
- What it's testing
- Moderate to severe neuropathic pain has a prevalence of 5% in the French population, involving the upper limb (UL) in 47%. Invasive neuromodulation, mainly spinal cord stimulation (SCS) is recommended as a third line treatment in refractory chronic neuropathic pain when optimized medical treatments are not sufficient to control pain.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Eligibility will be determined by trained clinicians with expertise in chronic pain and neuropathic pain.
- Patients between 18 and 80 years old
- suffering from moderate to severe (VAS score \>5/10) chronic (duration\> 12 months) neuropathic (DN4 score ≥ 4/10) unilateral pain - located in the...
- from peripheral origin, including complex regional pain syndrome type I and II, post-traumatic or post surgical pain.
- refractory to first and second line treatments for neuropathic pain according recent French recommendations and guidelines[6], including serotonin-...
You likely can't join if
- Brachial plexus avulsion
- Post-zoster neuropathic pain
- Phantom limb pain
- Patient unable to fill a self-administered questionnaire
- Patients with a chronic disease requiring repeated MRI monitoring
- Patients with contra-indication to general anesthesia, surgery or percutaneous BP approach.
See the full eligibility criteria
- Eligibility will be determined by trained clinicians with expertise in chronic pain and neuropathic pain.
- Patients between 18 and 80 years old
- suffering from moderate to severe (VAS score \>5/10) chronic (duration\> 12 months) neuropathic (DN4 score ≥ 4/10) unilateral pain - located in the upper limb.
- from peripheral origin, including complex regional pain syndrome type I and II, post-traumatic or post surgical pain.
- refractory to first and second line treatments for neuropathic pain according recent French recommendations and guidelines[6], including serotonin- noradrenaline reuptake inhibitor (SNRI) antidepressants (duloxetine and...
- Brachial plexus avulsion
- Post-zoster neuropathic pain
- Phantom limb pain
- Patient unable to fill a self-administered questionnaire
- Patients with a chronic disease requiring repeated MRI monitoring
- Patients with contra-indication to general anesthesia, surgery or percutaneous BP approach.
- Patients with other pacemakers (cardiac pacemaker or defibrillator) or patients with a high risk to use a defibrillator due to a known cardiac disorder.
- Patients with instable neuropsychological or psychiatric disorders
- Vulnerable patients: pregnant or breast feeding, minor, adult under guardianship or deprived freedom
The study team makes the final eligibility decision.
Where it's taking place
- Lyon, France, France
- Nice, France, France
- Poitiers, France, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 months to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Lyon, France, France; Nice, France, France; Poitiers, France, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.